Disease Domain | Count |
---|---|
Infectious Diseases | 14 |
Immune System Diseases | 5 |
Neoplasms | 3 |
Endocrinology and Metabolic Disease | 2 |
Top 5 Drug Type | Count |
---|---|
mRNA vaccine | 7 |
Vaccine | 5 |
Biological products | 2 |
Shared antigen vaccine | 2 |
Personalized antigen vaccine | 1 |
Top 5 Target | Count |
---|---|
SARS-CoV-2 S protein(SARS-CoV-2 S protein) | 6 |
KRAS(GTPase KRas) | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism KRAS modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date19 May 2022 |
Sponsor / Collaborator |
Start Date28 Feb 2022 |
Sponsor / Collaborator |
Start Date12 Feb 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
GRANITE-001 | Colorectal Cancer More | Phase 3 Clinical |
SLATE-001 ( KRAS ) | Pancreatic Cancer More | Phase 2 Clinical |
GRT-R904 | Colorectal Cancer More | Phase 2 |
T Cell-Enhanced samRNA (Gritstone) | COVID-19 More | Phase 1 |
GRT-R910 ( SARS-CoV-2 S protein ) | COVID-19 More | Phase 1 |